• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vericel Corporation - Common Stock (NQ:VCEL)

41.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Vericel (NASDAQ:VCEL): A Strong Growth Play With an Improving Technical Setup ↗
August 14, 2026
Via Chartmill
News headline image
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
August 11, 2026
News Provided by Biotech Insider on behalf of Conexeu Sciences Inc. 
From Biotech Insider
Via GlobeNewswire
Vericel Corp (NASDAQ:VCEL): Growth at a Reasonable Price ↗
August 11, 2026
Via Chartmill
News headline image
3 Major Earnings Winners You May Have Missed ↗
August 10, 2026
Vericel, Xenia Hotels & Resorts, and International Paper each posted Q2 2026 earnings with overlooked positives, from raised guidance to improved margins, despite mixed headline results. 
Via MarketBeat
Vericel (NASDAQ:VCEL) Beats Q2 Estimates, Raises Guidance, Shares Rise ↗
July 30, 2026
Via Chartmill
Vericel Corp (NASDAQ:VCEL): Strong Growth Stock With a Bull Flag Breakout Setup ↗
July 21, 2026
Via Chartmill
Vericel Corp (NASDAQ:VCEL): An Affordable Growth Stock at a Reasonable Valuation ↗
July 18, 2026
Via Chartmill
News headline image
Vericel Q2 Earnings Call Highlights ↗
July 30, 2026
Vericel (NASDAQ:VCEL) reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved... 
Via MarketBeat
Topics Earnings
News headline image
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
July 30, 2026
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
July 16, 2026
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests ↗
June 27, 2026
Focused on regenerative therapies for sports medicine and burn care, this biopharma firm reported a notable insider sale in June. 
Via The Motley Fool
Topics Regulatory Compliance
Vericel Corp (NASDAQ:VCEL): A Classic Affordable Growth Stock in Biotech ↗
June 26, 2026
Via Chartmill
Vericel Corp (NASDAQ:VCEL): Growth and Technical Setup Align for Potential Breakout ↗
June 16, 2026
Via Chartmill
Vericel (NASDAQ:VCEL) Balances High Growth and Reasonable Valuation in Affordable Growth Screen ↗
June 04, 2026
Via Chartmill
Vericel Corp (NASDAQ:VCEL): A Prime Example of Affordable Growth ↗
May 09, 2026
Via Chartmill
News headline image
Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself
June 18, 2026
From Biotech Insider
Via GlobeNewswire
News headline image
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
June 16, 2026
From World Street Intelligence
Via GlobeNewswire
News headline image
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
June 09, 2026
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
May 30, 2026
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
Via The Motley Fool
Topics Regulatory Compliance
Vericel Corp (NASDAQ:VCEL) Smashes Q1 Estimates, Raises Full-Year Outlook as MACI and Burn Care Surge ↗
May 07, 2026
Via Chartmill
Vericel Corp (NASDAQ:VCEL) Presents a Compelling Growth and Technical Setup Opportunity ↗
May 05, 2026
Via Chartmill
Vericel Corp (NASDAQ:VCEL) Emerges as a Top Affordable Growth Pick ↗
March 27, 2026
Via Chartmill
News headline image
MediWound (MDWD) Q1 2026 Earnings Transcript ↗
May 27, 2026
MediWound (MDWD) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
May 22, 2026
From Energy Metal News
Via GlobeNewswire
News headline image
Vericel Q1 Earnings Call Highlights ↗
May 09, 2026
Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as... 
Via MarketBeat
Topics Earnings
News headline image
Vericel (VCEL) Q1 2026 Earnings Transcript ↗
May 08, 2026
Vericel (VCEL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
May 07, 2026
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
April 23, 2026
From Vericel Corporation
Via GlobeNewswire
News headline image
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
April 02, 2026
From MediWound Ltd.
Via GlobeNewswire
News headline image
Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
April 02, 2026
From Vericel Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap